Indolent B-Cell lymphomas associated with HCV infection

Clinical and virological features and role of antiviral therapy

Luca Arcaini, Michele Merli, Stefano Volpetti, Sara Rattotti, Manuel Gotti, Francesco Zaja

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An increasing number of experiences confirmed the validity of this approach in marginal zone lymphomas and in other indolent NHL subtypes like lymphoplasmacytic lymphoma. Across different studies, overall response rate was approximately 75. Hematological responses resulted significantly associated with the eradication of the virus. This is the strongest evidence of a causative link between HCV and lymphomas. The aim of this paper is to illustrate the relationship between HCV infection and different subtypes of indolent B-cell lymphomas and to systematically summarize the data from the therapeutic studies that reported the use of antiviral treatment as hematological therapy in patients with HCV-associated indolent lymphomas.

Original languageEnglish
Article number638185
JournalClinical and Developmental Immunology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

B-Cell Lymphoma
Virus Diseases
Hepacivirus
Antiviral Agents
Lymphoma
Non-Hodgkin's Lymphoma
Italy
Therapeutics
Marginal Zone B-Cell Lymphoma
Ribavirin
Interferons
Epidemiologic Studies
Japan
Viruses

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy

Cite this

Indolent B-Cell lymphomas associated with HCV infection : Clinical and virological features and role of antiviral therapy. / Arcaini, Luca; Merli, Michele; Volpetti, Stefano; Rattotti, Sara; Gotti, Manuel; Zaja, Francesco.

In: Clinical and Developmental Immunology, Vol. 2012, 638185, 2012.

Research output: Contribution to journalArticle

@article{23d3a0d265e5439aa3b187b2ecc4eedf,
title = "Indolent B-Cell lymphomas associated with HCV infection: Clinical and virological features and role of antiviral therapy",
abstract = "The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An increasing number of experiences confirmed the validity of this approach in marginal zone lymphomas and in other indolent NHL subtypes like lymphoplasmacytic lymphoma. Across different studies, overall response rate was approximately 75. Hematological responses resulted significantly associated with the eradication of the virus. This is the strongest evidence of a causative link between HCV and lymphomas. The aim of this paper is to illustrate the relationship between HCV infection and different subtypes of indolent B-cell lymphomas and to systematically summarize the data from the therapeutic studies that reported the use of antiviral treatment as hematological therapy in patients with HCV-associated indolent lymphomas.",
author = "Luca Arcaini and Michele Merli and Stefano Volpetti and Sara Rattotti and Manuel Gotti and Francesco Zaja",
year = "2012",
doi = "10.1155/2012/638185",
language = "English",
volume = "2012",
journal = "Clinical and Developmental Immunology",
issn = "1740-2522",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Indolent B-Cell lymphomas associated with HCV infection

T2 - Clinical and virological features and role of antiviral therapy

AU - Arcaini, Luca

AU - Merli, Michele

AU - Volpetti, Stefano

AU - Rattotti, Sara

AU - Gotti, Manuel

AU - Zaja, Francesco

PY - 2012

Y1 - 2012

N2 - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An increasing number of experiences confirmed the validity of this approach in marginal zone lymphomas and in other indolent NHL subtypes like lymphoplasmacytic lymphoma. Across different studies, overall response rate was approximately 75. Hematological responses resulted significantly associated with the eradication of the virus. This is the strongest evidence of a causative link between HCV and lymphomas. The aim of this paper is to illustrate the relationship between HCV infection and different subtypes of indolent B-cell lymphomas and to systematically summarize the data from the therapeutic studies that reported the use of antiviral treatment as hematological therapy in patients with HCV-associated indolent lymphomas.

AB - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An increasing number of experiences confirmed the validity of this approach in marginal zone lymphomas and in other indolent NHL subtypes like lymphoplasmacytic lymphoma. Across different studies, overall response rate was approximately 75. Hematological responses resulted significantly associated with the eradication of the virus. This is the strongest evidence of a causative link between HCV and lymphomas. The aim of this paper is to illustrate the relationship between HCV infection and different subtypes of indolent B-cell lymphomas and to systematically summarize the data from the therapeutic studies that reported the use of antiviral treatment as hematological therapy in patients with HCV-associated indolent lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=84866131563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866131563&partnerID=8YFLogxK

U2 - 10.1155/2012/638185

DO - 10.1155/2012/638185

M3 - Article

VL - 2012

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

SN - 1740-2522

M1 - 638185

ER -